Abstract:Famotidine is an H2 receptor antagonist belonging to the BCS Class II, characterized by low solubility and limited oral bioavailability. The current study encompasses the formulation of novel famotidine phospholipid complex (FHC) with the aid of design of experiments (Central Composite Design) using solvent evaporation technique to overcome the disadvantages of Famotidine. To further enhance the physicochemical properties of FHC, it was incorporated into gastro-retentive floating tablets (GRDDS) using direct compression technique with sodium bicarbonate as a gas generating agent and its properties were compared to famotidine floating tablets. The pre-compression parameters, namely bulk density, tapped density, Hausner’s ratio, Carr’s compressibility index and angle of repose were evaluated. The flow properties of FHC granules were found to be better than the plain famotidine granules. The postcompression parameters, namely thickness, hardness, friability, weight variation, drug content and swelling index showed better results for FHC as compared to famotidine floating tablets. In-vitro buoyancy study indicated that the floating lag time for FHC tablets (110 ± 0.021 seconds) was higher than famotidine tablets (36 ± 0.033 seconds) owing to the higher molecular weight of phosphatidylcholine. But the total floating time for FHC tablets was found to be more than 18 hours and for famotidine tablets it was ~12 hours, indicating the improved residence time and buoyancy. The in-vitro dissolution study depicted that the cumulative release for FHC tablets (99.84 ± 0.058%) was enhanced 1.07 fold than Famotidine tablets (92.73 ± 0.028%) and 1.6 fold than marketed tablet, Famocid (62.24 ± 0.023%). When kinetic modeling was performed, famotidine tablet followed zero order kinetics, whereas FHC tablet followed Higuchi model indicating a modified and sustained release pattern. The statistical analysis for %cumulative release performed using ANOVA and Dunnett’s test showed the p-value to be below 0.05 (0.0043) indicating that the analysis model was significant. An accelerated stability study was performed for a period of 6 months at 25 ± 2°C; 60 ± 5% RH. FHC tablets showed a better stability profile than famotidine tablets. In conclusion, FHC gastro-retentive floating tablets showed improved flow properties, post compression properties, better drug content, improved in-vitro buoyancy and enhanced cumulative release and stability profile.

In Vitro Release Characteristic of Famotidine Bioadhesive Sustained-Release Tablets

Study on Correlation Between in vitro Release and in vivo Absorption of Captopril Delayed-onset, Sustained Release Tablet

Study on Correlation Between {\sl in Vitro} Release and {\sl in Vivo} Absorption of Captopril Delayed--onset, Sustained Release Tablet

Study on pramipexole dihydrochloride sustained-release tablets

Pharmacokinetics of Compound Famotidine Chewable Tablets in Healthy Volunteers

Formulation and Evaluation of Gastro-retentive Drug Delivery System of Novel Famotidine Phospholipid Complex

Preparation and in Vitro Release Study of Sodium Ferulate Gastric Floating Tablets

Selection of generic preparations of famotidine orally disintegrating tablets for use in unit-dose packages

Orally disintegrating tablets containing famotidine nanoparticles provide high intestinal absorbability via the energy-dependent endocytosis pathway

Self-made lovastatin/nicotinic acid sustained-release tablets and its pharmacokinetics in healthy volunteers

Montmorillonite-Famotidine/Chitosan Bio-nanocomposite Hydrogels as a Mucoadhesive/Gastroretentive Drug Delivery System

Studies on Preparation and in vitro Drug Release of Sodium Ferulate Double-layer Tablets

Release Characterization of Drugs in Hot-melt Pressure Sensitive Adhesive

Pharmacokinetics of compound famotidine chewing tablets in Chinese healthy volunteers after a single oral dose administration

Fabrication of Famotidine Loaded Sepiolite/Pectin Bionanocomposite Hydrogels for Controlled Drug Delivery

In vitro and in vivo studies on pulsatile release ta blets of diltiazem hydrochloride of the erosion-dispersion type

[Development of Sustained Release Tablet of Tamoxifen Citrate and Its in Vitro Release Profile].

Evaluation in vitro and in vivo of nifedipine controlled-release tablets

Distribution, Transition, Adhesion and Release of Insulin Loaded Nanoparticles in the Gut of Rats.

To evaluate In Vitro and In Vivo Performances of Mucoadhesive Microspheres of Aceclofenac

Pharmaceutical Equivalence of Film-Coated and Chewable Tablets: A Comparative Dissolution Study Using Pulverized Chewable Tablets